Drug Profile


Alternative Names: PLA-902

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Wyeth
  • Class Analgesics; Anti-inflammatories; Antiasthmatics; Antirheumatics; Benzoic acids; Chlorobenzenes; Small molecules; Sulfonamides
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Osteoarthritis; Pain; Rheumatoid arthritis

Most Recent Events

  • 11 Jan 2005 Discontinued - Phase-I for Pain in USA (unspecified route)
  • 11 Jan 2005 Phase-II clinical trials in Osteoarthritis in USA (unspecified route)
  • 11 Jan 2005 Phase-II clinical trials in Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top